Pharma 4.0

To achieve continued double digit growth and mitigate risks in R&D and manufacturing, pharma companies must gather actionable intelligence that will enable them to move rapidly from quantity-based, fee-for-service model to outcomes based contracts and adopt new digital platforms to deliver targeted therapeutics and improve profitability in a transformed healthcare market.

advanced medical technology

Frost & Sullivan’s Pharma 4.0 Research Program

The Pharma 4.0 program is centric to capture some of the most transformative pivots in the precision medicine landscape. It enables companies to stay ahead of the shift from small molecules to biologics, decode risks in contract research and manufacturing and embrace digital strategies to increase the value of new therapies. The team offers expert coverage on a variety of issues including portfolio management tools to expand in biosimilars, cell therapy and partnerships with Life Sciences IT companies to maximize operational excellence.

Expertise Areas

Frost & Sullivan’s expertise in pharma 4.0 research and consulting includes work in the following strategic and operational areas

Drug Development Icon

Contract Development & Manufacturing

Due to the growing demand for biologics & biosimilars, Contract Research Organizations (CRO) and Contract Development Manufacturing Organizations’ (CDMO) expertise in drug development will further disrupt the in-house–outsourced balance.  Our research coverage includes outsourcing services, bio-processing platforms, and single-use technologies.

Regenerative Medicine icon

Regenerative Medicine

Regenerative medicine is witnessing a surge in R&D activities with large-scale efforts from small to mid-segment companies with targeted therapeutic focus. Whilst the market is loaded with dermatological and musculoskeletal therapies, the approval of Kymriah by Novartis, and Yescarta by Gilead have brought in a fresh lease of hope for previously unresolved cancer cases.  Our research coverage includes Anti-Aging Therapies & Services and Cell & Gene Therapies.

Targeted Therapeutics

Targeted Therapeutics

The emergence of value-based reimbursement models and healthcare consumerism has provided a strong impetus to precision medicine. Investments across complex immunotherapies, alongside a strong potential for orphan drugs, are shifting the market paradigm towards M&A driven growth. Our research coverage includes immuno oncology therapies, bioengineered vaccines, cardiometabolic therapies,  neurodegenerative therapies, and biobetters.

Life Sciences Icon

Life Sciences IT

The increasing importance of patient centricity and digital continuity is driving higher utilization of big data analytics, cloud and AI-based platforms across industry value chain. This is evident from the recent partnerships forged by big pharmaceutical companies including GSK, Sanofi, Novartis, and Roche, with start-ups. We have identified 4 distinct pillars: Smart R&D, Connected Patient, Flexible Manufacturing and Digital Pharmacy to capture these trends. Our research coverage includes real-world evidence services, clinical trials data patient recruitment & monitoring solutions and the digital transformation of the pharma industry.


Book a complimentary one-hour Growth Pipeline Dialog™ session with our Healthcare & Life Sciences experts.

Greg Caressi

Greg Caressi has served in executive management roles, building and leading market analytics, growth advisory, and sales and business development teams. In addition to authoring numerous studies in his areas of focus, he has been involved in numerous strategic growth projects, with a focus on:

  • Next-generation technologies and technology adoption.
  • End-user and product/feature/pricing analysis.
  • International expansion strategies.
  • Competitive analysis.
  • M&A target analysis.
  • Detailed demand modeling.
  • Next-generation healthcare, with a focus on digital health, telehealth, data and analytics, and customer engagement solutions.
  • Healthcare and life science information technology.
  • Health IT infrastructure and platforms.

Greg has hands-on experience in international expansion strategies and implementation in Asia and Latin America and on-the-ground experience in China, Brazil, Mexico, Argentina, Colombia, and other developing economies. He has been a chairman, speaker, and trainer at industry conferences and events in the U.S., Asia, and Latin America.

Reenita Das

Reenita Das is a healthcare futurist and strategist, passionate about changing the healthcare industry. She was voted among the top 100 women in Femtech and Healthtech and the top 50 Healthcare strategists to follow in 2021. She has lived and worked in over 10 countries, focusing on healthcare issues and working with the public and private sectors to implement growth change strategies. She serves as Partner and Senior Vice President and is the first woman Partner at Frost & Sullivan.

Her areas of interest in identifying growth opportunities include:

  • Women’s health.
  • Digital health.
  • Precision diagnostics and precision medicine.
  • Chronic disease management.

Dinesh Sampath Rangaraj

Dinesh is passionate about building organizations and helping them grow. He has over 20 years of experience advising clients across healthcare, semiconductors, and information, communication, and technology sectors. As Senior Vice President and Principal, Dinesh works as a trusted advisor to senior leadership at companies to drive growth and be ready for the future. His areas of expertise include:

  • Business strategy.
  • M&A and partnerships.
  • Business model transformation.
  • Sales and marketing strategy.
  • Product portfolio strategy.
Vice President, Growth Opportunity Analytics, Global Practice Area Leader - Healthcare & Life Sciences

Nitin Naik

With more than 24 years of industry experience, Nitin serves as Frost & Sullivan’s Global Practice Area Leader (HLS). In this role, he is dedicated to executing strategy consulting, forecasting analytics, commercial due diligence and clinical R&D projects for healthcare companies.

Nitin has a strong understanding of the dynamics in the healthcare industry and possesses domain knowledge in the life sciences space. He has advised several mid sized companies and start-ups in numerous commercial transactions and IPOs to optimize market positioning and valuation strategies.

He has led strategic initiatives with Medical Device & Life Science companies:

  • Emerging markets go to market strategy , Innovative therapies portfolio analysis
  • Sales, Marketing, Distribution planning
  • Global Alliances, Public Private Partnerships, M&A.
  • Co-innovation programs, research
Sr Vice President, Growth Pipeline Advisory and Delivery Global Practice Area Leader - Healthcare & Life Sciences

Sujith Eramangalath

Vice President, Growth Pipeline Advisory and Delivery, Americas - Healthcare & Life Sciences

Charlie Whelan

Charlie leads Frost & Sullivan’s growth consulting practice in the Americas supporting clients across the healthcare technology and services ecosystem. His responsibilities include project management, business development, strategic planning and subject matter expertise, particularly in the medical devices market.

Vice President, Growth Pipeline Advisory and Delivery, Europe - Healthcare & Life Sciences

Siddharth Saha

Vice President, Growth Pipeline Advisory and Delivery, Asia Pacific - Healthcare & Life Sciences

Milind Sabnis

Consulting Director, South Asia

Sowmya Srinath

Research Manager, Healthcare & Life Sciences

Siddharth Shah

Siddharth (Sid) Shah leads the global medtech research program of the Healthcare & Life Sciences practice, and has over ten years of healthcare market research & consulting experience. In his prior life he has also conducted wet lab research in stem cells at the prestigious Johns Hopkins University. Beyond medical devices, Shah also tracks innovations in radiology artificial intelligence, diabetes, and connected devices. He holds a Master of Science in Biotechnology from the Johns Hopkins University.

Director - Healthcare & Life Sciences

Unmesh Lal

Consulting Director, Life Sciences

Christi Bird

Consulting Director, Digital Health, Medical Imaging & Informatics

Daniel Ruppar

Consulting Director, Europe & Israel

Paljit Sohal

Senior Director, Growth Pipeline Advisory and Delivery, Asia Pacific - Healthcare & Life Sciences

Kiranjit Kaur

Consulting Director, Asia Pacific

Rathanesh Ramasundram

Consulting Leader, Growth Pipeline Advisory & Delivery, Middle East & Africa

Daniel I’Anson

Daniel leads the growth consulting practice for Healthcare & Life Sciences in the Middle East & Africa. This practice covers Healthcare Delivery & Operations, Medical Imaging & Informatics, Pharmaceuticals & Life Sciences, and Digital Health.

Daniel is a seasoned healthcare professional with more than 15 years’ experience in the healthcare industry and has extensive experience supporting clients to achieve their strategic growth objectives through Optimization, Efficiency, Quality and Cost Initiatives; Market Analysis, Customer VOC/Perception studies, Due Diligence, and Service Expansion; Healthcare Data and Analytics; Change, Program and Project Management; and, Leadership Development.

Senior Industry Analyst, Medical Imaging & Informatics

Imran Khan

Imran has over 20 years of experience in market research and consulting, covering a range of information and communication technologies across multiple industry verticals and enterprise and consumer segments.

Industry Principal, Digital Health

Victor Camlek

Industry Principal, Digital Health

Koustav Chatterjee

Senior Industry Analyst, Digital Health

Chandni Mathur

Industry Principal, Americas

Patrick Riley

Value Proposition

The Pharma 2.0 team utilizes a proven methodology that leverages Frost & Sullivan’s proprietary forecast models, access to high-quality internal and external published content, and information gained from primary research interviews. We have developed a strong network of key opinion leaders and subject matter experts who partner with us to develop futuristic insights. Most projects also leverage our proprietary market models that enable us to develop mid-range (5 year) and long range (10 year) forecasts based on inputs from primary research.